Immuno-effect of Tα1 for Stage I NSCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Immuno-effect of Tα1 for Stage I NSCLC — Stella

Home/Non Small Cell Lung Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Non Small Cell Lung Cancer trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality

Key details

Sponsor

Yousheng Mao

Enrollment target

~40 participants

Started

June 2024

Primary completion

September 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated September 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.